New pneumonia vaccine shows promise in early trial
NCT ID NCT05092386
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 13 times
Summary
This early-stage trial tested a new 13-valent pneumococcal conjugate vaccine in 310 healthy people, from infants 6 weeks old to adults 49 years. The goal was to check the vaccine's safety and how well it triggers the immune system to fight pneumococcal bacteria, which can cause pneumonia and other serious infections. Results will help decide if larger studies are warranted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Center for Diseases Control and Prevention
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.